Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Status:
Completed
Trial end date:
2017-12-20
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind and placebo controlled phase 3 study to evaluate the
efficacy and safety of F-627 in women with stage II-IV breast cancer receiving chemotherapy
treatment.